Plexus Announces Fiscal Second Quarter Financial Results
- Fiscal second quarter 2021 revenue of $881 million, compared to $767 million in the same quarter 2020.
- GAAP diluted EPS of $1.42, including $0.07 of restructuring charges and $0.22 of stock-based compensation expense
- Initiates fiscal third quarter 2021 revenue guidance of $875 to $915 million with GAAP diluted EPS guidance of $1.23 to $1.38, excluding any unforeseen COVID-19 impacts.
Todd Kelsey, President and CEO, commented, “Our robust fiscal second quarter results highlight the advantages of our unique value proposition and consistent focus on operational excellence. Our GAAP operating margin of 5.75% expanded 11 basis points from the prior quarter, representing the best performance in more than a decade and the fourth consecutive quarter in excess of 5.0%. Productivity gains, expense management and another solid performance from our Engineering Solutions team contributed to better than anticipated profitability. Revenue of $881 million was in line with our expectation and at the midpoint of our guidance. Through this combination, we delivered GAAP EPS of $1.42, which exceeded the top end of our guidance range.”
Mr. Kelsey continued, “Leveraging the record $3.3 billion funnel of qualified manufacturing opportunities from our fiscal first quarter, we won 42 new manufacturing programs. For the second consecutive quarter, these program wins include a number of meaningful new customer engagements, positioning us for further growth. These wins, which include a notable Aftermarket Services engagement, represent $284 million in annualized revenue when fully ramped into production and contribute to our trailing four quarter wins, once again, exceeding $1.0 billion.”
Patrick Jermain, Executive Vice President and CFO, commented, “With our exceptional operating performance and working capital management, we delivered return on invested capital of 17.3%, sequentially improved by 100 basis points and the highest return delivered in four years. This result generated economic return of 920 basis points above our weighted average cost of capital, creating considerable shareholder value. Further, given the strength of our balance sheet and free cash flow generation, we elected to repay our 364-day term loan of $138 million three months early. We ended the quarter with ample liquidity given our cash balance of approximately $295 million and only $38 million borrowed under our $350 million revolving credit facility. In addition, we reconfirm our fiscal 2021 expectation for free cash flow of approximately $100 million.”
Mr. Kelsey further commented, “We anticipate our robust performance will continue for the fiscal third quarter based upon incrementally stronger demand, particularly in our Healthcare/Life Sciences sector, and confidence in our ability to consistently execute. We are guiding revenue of $875 to $915 million, GAAP operating margin of 5.1% to 5.6% and GAAP EPS of $1.23 to $1.38. Our guidance assumes that neither supply chain constraints, which are a near term limiter in our ability to meet customer demand upside, nor COVID-19 will materially impact end markets or our operations beyond what is already anticipated.”
Mr. Kelsey concluded, “We believe we have a platform to sustain strong revenue growth moving forward through the strengthening in the overall demand environment, including equipment used in elective medical procedures, an eventual commercial aerospace market recovery, our ability to support secular growth markets and the acceleration in new program wins. Looking beyond fiscal 2021, we are confident these factors support our goal to achieve 9% to 12% annual revenue growth while continuing to deliver industry leading operating performance.”